148 related articles for article (PubMed ID: 33310117)
1. Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences.
Cimolai N
Int J Antimicrob Agents; 2021 Mar; 57(3):106257. PubMed ID: 33310117
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences.
Cimolai N
Int J Antimicrob Agents; 2021 Mar; 57(3):106258. PubMed ID: 33310116
[TBL] [Abstract][Full Text] [Related]
4. Effect of Macrolides and β-lactams on Clearance of Bordetella pertussis in the Nasopharynx in Children With Whooping Cough.
Mi YM; Hua CZ; Fang C; Liu JJ; Xie YP; Lin LN; Wang GL
Pediatr Infect Dis J; 2021 Feb; 40(2):87-90. PubMed ID: 33021592
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006-2017.
Lönnqvist E; Barkoff AM; Mertsola J; He Q
J Glob Antimicrob Resist; 2018 Sep; 14():12-16. PubMed ID: 29486357
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario, Canada.
Marchand-Austin A; Memari N; Patel SN; Tang P; Deeks SL; Jamieson FB; Crowcroft NS; Farrell DJ
Int J Antimicrob Agents; 2014 Jul; 44(1):82-4. PubMed ID: 24837412
[No Abstract] [Full Text] [Related]
7. The First Report of Macrolide-Resistant Bordetella pertussis Isolation in Japan.
Yamaguchi T; Kawasaki Y; Katsukawa C; Kawahara R; Kawatsu K
Jpn J Infect Dis; 2020 Sep; 73(5):361-362. PubMed ID: 32350216
[TBL] [Abstract][Full Text] [Related]
8. Where macrolide resistance is prevalent.
Li Y; Liu X; Zhang B; He Q; Wang Z
APMIS; 2015 Apr; 123(4):361-3. PubMed ID: 25703275
[No Abstract] [Full Text] [Related]
9. High Prevalence of Macrolide-Resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014-2016.
Li L; Deng J; Ma X; Zhou K; Meng Q; Yuan L; Shi W; Wang Q; Li Y; Yao K
Emerg Infect Dis; 2019 Dec; 25(12):2205-2214. PubMed ID: 31742507
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility testing of Bordetella pertussis in Taiwan prompted by a case of pertussis in a paediatric patient.
Yao SM; Liaw GJ; Chen YY; Yen MH; Chen YH; Mu JJ; Chiang CS
J Med Microbiol; 2008 Dec; 57(Pt 12):1577-1580. PubMed ID: 19018032
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics for whooping cough (pertussis).
Altunaiji S; Kukuruzovic R; Curtis N; Massie J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004404. PubMed ID: 15674946
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibility to macrolide antibiotics of Bordetella pertussis and Bordetella parapertussis strains isolated from whooping cough patients in 1968 and in 1997-99].
Chodorowska M; Kuklińska D; Tyski S
Med Dosw Mikrobiol; 2001; 53(1):39-43. PubMed ID: 11757403
[TBL] [Abstract][Full Text] [Related]
13. Challenges and prospects in treating macrolide-resistant Bordetella pertussis in Chinese paediatric practice.
Yang R; Xu H; Zhang Z; Liu Q; Wu X
J Infect; 2024 Jul; 89(1):106185. PubMed ID: 38763390
[No Abstract] [Full Text] [Related]
14. [Susceptibility testing and molecular epidemiology of clinical strains of Bordetella pertussis isolated in Japan from 2001 to 2002].
Ohtsuka M; Kikuchi K; Okada K; Higashide M; Shundo K; Sunakawa K
Kansenshogaku Zasshi; 2004 May; 78(5):420-7. PubMed ID: 15211864
[TBL] [Abstract][Full Text] [Related]
15. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.
Hoppe JE
Infection; 1998; 26(4):242-6. PubMed ID: 9717684
[No Abstract] [Full Text] [Related]
16. Shattering a myth - Whooping cough susceptible to antibiotics.
Syed MA; Jamil B; Bokhari H
Pak J Pharm Sci; 2016 May; 29(3):985-90. PubMed ID: 27166543
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of macrolides against Bordetella pertussis strains isolated in 1968 and 30 years later in Poland.
Chodorowska M; Tyski S; Kuklińska D
Clin Microbiol Infect; 2000 Jan; 6(1):50-2. PubMed ID: 11168039
[No Abstract] [Full Text] [Related]
18. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015.
Jakubů V; Zavadilová J; Fabiánová K; Urbášková P
Cent Eur J Public Health; 2017 Dec; 25(4):282-286. PubMed ID: 29346850
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Susceptibility and Molecular Detection of Pertactin-producing and Pertactin-Deficient Bordetella pertussis.
Souder E; Vodzak J; Evangelista AT; Long SS
Pediatr Infect Dis J; 2017 Jan; 36(1):119-121. PubMed ID: 27956730
[TBL] [Abstract][Full Text] [Related]
20. Modifying antibiotic treatment strategies in the face of pertussis surge associated to erythromycin resistance in China.
Shi W; Meng Q; Hu Y; Yao K
J Infect; 2024 Jun; 88(6):106174. PubMed ID: 38719109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
